A股異動丨和邦生物(603077.SH)一字漲停 孫公司擬30億元投建年產8GW光伏封裝材料及製品項目
格隆匯12月28日丨和邦生物(603077.SH)一字漲停,報1.52元,總市值134億元。和邦生物上週五盤後公佈,公司全資子公司四川武駿特種玻璃製品有限公司之全資子公司武駿重慶光能有限公司於2020年12月24日與重慶市江津區白沙工業園發展中心簽訂《武駿重慶光能有限公司年產8GW光伏封裝材料及製品項目投資協議》,預計總投資約30億元人民幣。此項目實施後,將進一步優化公司產業佈局,增強企業的競爭力,符合公司的長遠發展規劃及全體股東的利益,有利於公司的可持續發展。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.